The efficacy of a photolyase-based device on the cancerization field: a clinical and thermographic study by unknown
RESEARCH Open Access
The efficacy of a photolyase-based device
on the cancerization field: a clinical and
thermographic study
Luigi Laino1, Fulvia Elia2*, Flora Desiderio2, Alessandra Scarabello3, Isabella Sperduti4, Carlo Cota5 and Aldo DiCarlo6
Abstract
Background: At skin level, a cancerization field (CF) indicates some chronically photoexposed areas in which, besides
a primary tumor, histological or biomolecular modifications without clinical signs are present. Active telethermography
(ATT) allows us to observe the imaging of a hyperthermic halo (HH) surrounding the tumor . The Authors hypothesize
HH as a possible expression of CF.
Objectives: The aim of this study were to verify whether HHs have the same histological or immunohistochemical
characteristics as the CF and, secondly, to evaluate the efficacy of a device containing the enzyme photolyase in
modifying thermographic parameters in these area.
Methods: The study included 30 patients affected by actinic keratosis, evaluated clinically and by ATT at time 0
and after 3, 6 and 9 months.
Results: The ATT showed the presence of HHs in all the patients and, after the treatment, a significant modification of
both the extension of these areas and the thermal parameters. In 5 patients for whom, while operated, two other
biopsies were performed, respectively on the HH and on a perilesional non-hyperthermic area, in the HH, we detected
a p53 and Ki 67 over-expression.
Conclusions: Our results indicate that ATT could represent a useful paraclinic method in identifying CFs in
subjects at risk.
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Introduction
Actinic keratosis (AK) is one of the most frequent skin
tumors, affecting in particular the Caucasian population
[1–4]. Such lesions are mainly located in sun-exposed
areas, i.e. head, face, and arms. Elderly people, in particu-
lar farmers and sailors, as well as individuals who have
undergone immunosuppressive treatments or are chronic-
ally exposed to arsenic and tar, are at increased risk of AK
[5, 6]. Some important co-factors are, the skin phototype
(type I and II according to the Fitzpatrick classification),
baldness, genetic predisposition, sun exposure or burns in
childhood and UV-A treatments [7–10]. Clinically, AK is
characterized by erithematous or brown lesions with a
diameter of less than 1 cm, showing a hyperkeratotic
surface, sometimes erosive, and well-defined edges. Histo-
logically, AK is an in situ squamous cell carcinoma (SCC)
and its progression to SCC ranges from 0.25 to 16 % of
cases, as reported in the literature [11–13]. AK lesions are
often not unique, and patients may experience new lesions
in the same area, which can appear concomitant or later,
in the course of the years. Moreover, in this region, the de-
velopment of other malignant skin tumors such as SCC or
basocellular carcinoma (BCC), after the primary AK, is
also possible. This particular behavior corresponds to the
concept of “cancerization field” (CF), as proposed by
Slaughter in 1953 [14]. As a general characteristic, CF
indicates the risk of having a second tumor in the same
area after the removal of the first one. This preneoplas-
tic condition, described initially in the oral mucosa, has
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been successively reported in internal organs and in the
skin. At the cutaneous level, CF is addressed to the
chronically photoexposed area of the head, particularly
in the fair-skinned individuals that, after a first diagno-
sis of AK or other non-melanoma skin cancer (NMSC),
can in the future present one or more malignant lesions
in the same site. Indeed, according to Slaughter [14],
other Authors found some peculiar histological and
biomolecular modifications in these critical areas, even
in the absence of clinical signs. In fact, at the histo-
logical level, there have been reports of loss of cell po-
larity, disorganization, and hyper- and para-keratosis
associated with dermal modifications (elastosis, vascu-
lar ectasia, reduction of collagen fibers) [15]. Immuno-
histochemically, some mutations of important genes
e.g. p53, Bcl 212, Ki 67, p21, CPI-17, PCNA, MMP-1,
and also alterations of pro-collagen 1 and tenascin-C
have been demonstrated [16, 17]. In addition, in experi-
mental models, some Authors have described, the produc-
tion of a high number of cyclobutane pyrimidine dimers
(CPD), the major DNA photoproducts of UV radia-
tions, in the CF [18].
Given the foregoing, the study of CF is very import-
ant for the monitoring of individuals already treated
for AK, with the aim of preventing a second tumor. To
this purpose, many non-invasive methods have been
employed in order to identify these areas at risk, such
as dermoscopy and confocal microscopy [19, 20]. Also,
mathematical models have been proposed [21]. Tele-
thermography (TT) is a non-invasive method that
collects the infrared radiation emitted from the body
and creates an electronic image [22, 23]. Since its first
description by Brasfield [24], many Authors have observed
that malignant tumors of the skin, such as melanoma and
SCC, show a “hot” pattern, while benign lesions (e.g. seb-
orrheic warts), and BCC appear as “cold” [24, 25]. In those
area, thermal values, particularly in large nodular forms,
could reach even 3-4 °C. However, if the tumoral le-
sions are small (e.g. diameter <1 cm), they could be
thermographically undetectable or “missed” (as Bras-
field first noted) [24], particularly when the lesions are
sited in physiological “hot” regions (e.g. groin, axilla)
(false negatives). The principle of dynamic or active
telethermography (ATT) is that, by cooling or heating
by air or by gel packs the skin for a defined period of
time, is possible to better observe the specific pattern
of the tumor. This pattern appears rapidly (in seconds)
in the course of the thermal recovering of the area
after the removal of the stimulation, in contrast with
the thermal recovery of the perilesional healthy skin
(in minutes) [25, 26]. The thermal recovery time
(TRT) is the interval between t0 and the time that sin-
gle thermal points come back to the steady state
(expressed in seconds, or minute). The first advantage
of the method is the possibility to evaluate very small
malignant lesions that, having a reduced critical mass,
are difficult to observe using direct thermography. Fur-
thermore, thermostimulation does not require climatiz-
ing of the operating room, the thermal recovery being
independent of the normal working conditions of the
room. In melanoma studies, we found TT useful for
the diagnosis of in-transit metastases from melanoma
[27, 28]. Some methods use a periodic thermal modula-
tion, e.g. lock-in thermal imaging (LIT) [29].
Introducing the “thermostimulation” method in 1995,
our intent was to perform a thermal stress under con-
trolled conditions, and following the transient temperature
measurement [30]. By selecting the infrared imaging
at a specific time after thermostimulation, it is pos-
sible to “reject” the effect of local steady state and to
select the peculiar thermographic pattern of the le-
sions. For this procedure, a special equipment has
been adopted, namely the thermostimulator (Reg.
Italy. Patent 1323870/IT/2001) [29] (see Methods). In
a recent paper, we demonstrate by using ATT that AK
has not only a “hot” pattern and a rapid TRT but it is
surrounded by a hyperthermic halo (HH), whose thermal
intensity (Δt) appears lower than that of the tumor. This
HH expands generally for 2–4 cm2 around the clinical
lesion [30].
On these premises, our hypothesis was that HH could
correspond to the CF. To demonstrate this, the aim of
this study was to verify whether, in the HH area were
present, at histological and immunohistochemical level,
the same changes present in the CF, as reported in
literature [30–32]. Furthermore, we proposed to verify
by this method the efficacy of the compound EryfotonaR
in reducing the degree and the extension of the HH.
Eryfotona is a film-forming medical device in fluid
formulation containing a DNA-repair enzyme photo-
lyase and a high-protection UV filter (Repairsomes™)
that is indicated in the treatment of CF in patients
affected by AK. Previous studies have shown that
Eryfotona is effective in treating and preventing the ab-
normal histological and biomolecular cellular pattern
of CF [31–35].
Patients and methods
Patients and Eryfotona treatment
A group of 30 patients affected by AK, respectively 27
males and 3 females, referred to our Institute in the
period January-April 2013. The age ranged from 55 to
75 years (mean = 64.3 years). All the patients had photo-
type I-II, and a personal history of prolonged exposure
to sun rays, for professional or recreational reasons-
respectively 14 farmers, 4 sailors, 4 lifeguards, while the
other 8 lived near the sea. Most of them (27/30 patients)
had baldness at an advanced stage, while all female
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patients had androgenic alopecia with severe baldness in
the temporo-frontal region. The AK lesions were mainly
sited in the temporo-parietal, frontal and occipital
regions.
Treatment with Eryfotona started 15 days after sur-
gical removal of the lesions. Eryfotona was applied
daily (at 8 and 12 h) by the patient in the areas con-
cerned, at a standard dose for 9 months. Written in-
formed consent was obtained from all patients, and
the study was approved by the institutional research
board and conducted according to the Declaration of
Helsinki Principles. Three drop-outs for poor compli-
ance (Patients n 7, 8, 10) were reported.
Active telethermography (ATT)
For this procedure we employed a FLIR3000 Thermo-
cam™ together with the thermostimulation method. We
used a special equipment, namely the thermostimulator
(Reg. Italy. Patent 1323870/IT/2001) [29] consisting of a
small insulated tank containing 5 l of a mixture of alco-
hol and water at 50 % and connected through a two-way
tube to the probe, a rubber balloon with a capacity of
250 ml. The mixture can be led to a preset temperature,
by means of a heating-cooling system put inside the
walls of the tank (range possibility: from 0 °C to 40 °C).
The temperature of the liquid in the container and the
time of application are displayed on monitors. After the
mixture reaches the set temperature (in our study: +5 °C),
the liquid is driven at high speed by means of the pump to
fill the balloon. Then, the balloon is rested on the skin
for 20 s. The moment when stress is removed (= t0),
the whole stimulated skin area has homogenously a
thermal value of +5 °C. The area of the hyperthermic
halo (HH) is automatically calculated by a simple func-
tion of the PC connected with the thermocamera. To
ensure that the same skin surface is observed at each
examination, we used a specific function of the PC con-
nected to the thermocamera, and in case of several
lesions, a cutaneous marker was used. Thermal recov-
ery time (TRT) is the interval between t0 and the time
that single thermal points come back to the steady
state (expressed in seconds, or minute). Clinical and
thermographic evaluations were planned respectively
at time 0, and 3, 6 and 9 months of treatment. TRT
was considered as rapid (R) for values <10 s, slow (S)
for values >10 s and < 2 min, and normal (N) for values
of healthy perilesional skin (>2 min).
Immunohistochemistry
In 5 of the subjects (n = 30), two punch biopsies were
also performed during the surgical removal of AK,
respectively, one in the area of HH and the other in a
perilesional non-hyperthermic area. All specimens were
processed using the standard histopathologic method of
paraffin embedding sectioning and hematoxylin-eosin
(HE) staining. In these 5 patients, in addition to histo-
logical evaluation, an immunohistochemical test for p53
and Ki67 was also conducted.
Statistical analyses
Descriptive statistics were used to represent study results
as percentages and medians (range). A Friedman test for
non-parametric data was used to test changes in each
variable over time, while a McNemar test was used for
paired data. The SPSS (21.0) statistical program was
used for analysis.
Fig. 1 a AK of the scalp. b TTG of the scalp. Note the hyperthermic “halo”, while squamous crusts make the AK lesion itself apparently “cold”
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Results
The thermographic presence of HH was observed in all
the patients before the surgical removal of AK. These
HHs extended from few mm2 to some cm2 (mean
3.46 cm2), and their TRTs, very rapid at baseline, showed
generally progressive increase at each control (Fig. 1 and
Table 1). In the 27 patients that completed the study,
after treatment with Eryfotona we observed that the area
of the HHs declined from a mean of 3.46 cm2 at baseline
to a mean of 0.64 cm2 at 9 months, while the values of
TRT progressively increased toward the perilesional
values of the healthy skin (>2 min) (Table 1). In 5 cases,
the HH disappeared completely. In parallel, at each
periodic control, the TRT values showed a progressive
tendency to the same values as the perilesional healthy
skin. In those 5 patients in which a double biopsy was
performed, in the HH site, we observed, histologically, a
more or less marked actinic elastosis and p53 and Ki 67
overexpression in the epidermis (Fig. 2). These data were
less evident or absent in the non-hyperthermic perile-
sional site (data not shown).
Discussion
The term “cancerization field” (CF) was initially intro-
duced by Slaughter for describing the presence in the
oral cavity of some histological alterations besides or
Table 1 Evolution of the hyperthermic halo (HH) in 27 patients. The diagram shows, respectively, its extension (in cm2) and RTR
Baseline I Check (3 Months) II Check (6 Months) III Check (9 Months)
Patient Lesion site HH Area TRT
(a)
HH Area TRT HH Area TRT HH Area TRT
(cm2) (cm2) (cm2) (cm2)
1 Frontotemporal 5 R 4 R 2 R 1 S
2 Frontoparietal 4 R 3 R 1 S 0,5 S
3 Frontoparietal 4 R 3 R 1 R 0,5 S
4 Temporal 3 R 2 R 1 S 1 S
5 Frontotemporal 3 R 2 R 1 R 0 N
6 Occipital 5 R 4 R 1 R 0 N
7 Occipital 4 R 3 R Drop-out
8 Occipital 3 R 2 R 2 R Drop-out
9 Temporal 5 R 3 R 1 R 1 S
10 Frontoparietal 4 R 3 R Drop-out
11 Occipital 3 R 2 S 1 S 0 N
12 Frontal 2 R 2 R 1 S 1 S
13 Parietal 5 R 4 R 3 R 1 S
14 Occipital 3 R 2 R 1 R 0,5 S
15 Occipital 2 R 1 R 0,5 N 0 N
16 Frontotemporal 3 R 2 R 1 N 1 R
17 Frontoparietal 4 R 3 R 2 R 1 R
18 Parieto-temporal 2 R 1 R 1 R 0,5 S
19 Temporal 4 R 3 R 2 N 0,5 S
20 Frontotemporal 4 R 3 R 2 R 0,5 S
21 Temporo-occipital 2 R 1 R 1 R 0,5 S
S22 Frontoparietal 3 R 2 S 1 S 1 S
23 Occipital 4 R 3 S 2 S 1 R
24 Temporal 5 R 4 R 3 R 0,8 SN
25 Frontoparietal 3 R 2 R 1 S 0,5 SN
26 Occipital 2 R 1 S 0,5 S 0,5 S
27 Frontal 2 R 1 R 1 S 0,6 S
28 Parietal 3 R 2 R 1 R 0,5 S
29 Occipital 4 R 3 R 2 R 1 S
30 Frontal 4 R 3 R 2 R 0 N
(a)TRT = Thermal recovery times. Rapid (<10 s): Slow (>10 s < 2 min); Normal (>2′)
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near the primary tumor, in the absence of clinical evi-
dence. For this reason, he expressed the concept of CF as
a “benign epithelium preconditioned to change toward
cancer” [14]. The possibility of a gradual progression from
subclinic condition to a clinically detectable SCC was also
confirmed by other Authors [15–18]. At skin level, the
most significant example of CF is considered the sun-
exposed areas of individual at risk, in which also AKs and
other NMSC are frequently observed. Among non-
invasive methods proposed to identify these areas, the
ATT method uniquely allow us to observe in imaging
the presence of the HH that could be the visible
expression of CF. Thermographically, HH is defined as
a hyperthermic halo surrounding the AK lesion. Its
identification is possible by means of ATT that shows
its quick thermal recovery and its particular morph-
ology (asymmetric hyperthermic halo). Introducing the
“thermostimulation” method in 1995, our intent was to
perform a thermal stress under controlled conditions, and
following the transient temperature measurement [29]. In
our previous studies, based always on the same parameters
(+5 °C × 20″), we report a value of TRT >2 min in the case
of healthy skin, in agreement with others [25, 26]. On an
average evaluation, the thermal difference among tumor,
HH and perilesional healthy skin, are often <0.01 °C, lead-
ing to “miss” these hot spot being low the current accur-
acy/sensitivity of the ATT devices for this purpose. The
thermostimulation method let us to easily overpass the
problem of the direct ATT by switching the thermographic
static values (in °C) with the times of recovery expressed in
min/s. TRTs in case of malignant tumor are in general of
the order of second, while those of the healthy are in the
order of minutes, according to our parameters of thermal
stress (+5 °C × 20”). In our observations, HH has a less
rapid thermal recovery respect to the tumor as it is
reported in the Table 1. In the case of malignant tumors of
the skin, such as SCC and malignant melanoma, we
observe, few seconds after t0, the thermal image of the
tumor as a hot spot, while residual field is still cold
[25, 26]. However, in cases of basocellular carcinoma,
we have noted a long persistence of hypothermia after
the thermostimulation (an order of minutes) as hap-
pens also for other pigmented benign lesions (e.g. seb-
orrheic warts) [29]. The molecular mechanisms of HH
are not clear. Possible explanation has be suggested to
be the high esothermic metabolism of the malignant
tumors in contrast to other lesions such as basalioma
[26]. In agreement with this hypothesis, we found, in
the 5 cases in which we performed the perilesional
biopsies, overexpression of Ki 67 and p53, the latter
indicative of gene mutation, particularly in the corres-
pondence of HH that is suggestive of tumor transform-
ation. Recent studies in molecular genetics hypothesize
a carcinogenetic model based on the clonal expansion
of genetically modified cells following the chronic ac-
tion of UV radiations. In particular, DNA-modifying
UV-A and, to greater degree, UV-B and RNA structure
foster the formation of CPD with subsequent muta-
tions of the telomerase or oncosuppressor p53 gene
[19]. However, to confirm our hypothesis, it is neces-
sary to have more data, in particular, a larger number
of patients and samples.
The reason for the enrolment of a small number of
patients to evaluate the histological and immunohisto-
chemical studies of HH (5 subjects) was due to the fact
that the principal end-point of this paper was to confirm
by means of ATT the presence of HH in all the patients
affected by AK. Then, we performed the immunohisto-
chemical tests only in those patients that consented to
more biopsies. EryfotonaR proved effective in reducing
the extension of HHs and their thermal values in our 27
subjects after a treatment of 9 months. The mechanism
of action of Eryfotona is dual, a preventive one of the
UV-block by means of a strong sunscreen and a molecu-
lar enzymatic action on DNA (photolyase). Furthermore,
topical application of liposome formulations with CPD
Fig. 2 a Histologic examination of skin biopsy from cancerization field. The epidermis appears normal without evident atypia of the keratinocytes.
In the dermis, marked actinic elastosis is present. b Proliferating cell in suprabasal layers, as marked with Ki67. c p53 expression of the epidermis
in corresponding area of cancerization field (arrow)
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photolyases onto human skin provides protection against
UVB-induced damage [36-37]. Finally, patients declared,
from the first control, a sharp reduction, in most cases a
complete resolution, of the itchiness and/or pain referred
to the lesional and perilesional area.
In conclusion, among the non-invasive methods from
time to time proposed in the study of CF, ATT could
represent a useful paraclinic method in identifying CF in
subjects at risk. Thermography has a long story in clin-
ical applications, but thermal imaging in dermatology is
not much employed and the papers on this issue are
very few among dermatologists, the specialists that could
benefit most in this field. This method is easy to use,
gives an immediate response, and is repeatable and
reproducible. For this reason, ATT could be very useful
for epidemiological controls in some groups at risk, in
the follow-up of operated patients, and in the assess-
ment of the efficacy of proposed treatments.
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